Our Why
unlocking the cell to provide a complete picture of the
fetal genome. Mothers, families and physicians will now be
able to receive definitive information delivered at the
earliest stages of pregnancy.
Core Advantages
Currently, blood-based NIPT offers the highest level of performance for aneuploidy screening but it is inherently limited by relying on measuring low-abundance circulating DNA fragments. In contrast, Cradle’s patented technology isolates and utilizes intact cells at high purity leading to the following core advantages:
- Earliest prenatal testing available
- Highest accuracy in a non-invasive test
- No patient limitations
- Comprehensive genome analysis
- Future testing for pregnancy complications
Sample Collection & Preservation
Cells are quickly and safely collected at the clinic, using a
routine, FDA approved and non-invasive procedure. The
sample is then stabilized and shipped to Cradle for analysis.
Our Lab Process
Cell Isolation
Fetal EVT cells are captured and purified using
a proprietary magnetic separation process
Fetal DNA Purification
High purity DNA is extracted from collected fetal EVT cells
Comprehensive Genome Analysis
Fetal DNA is analyzed on a genome sequencer
Interpretation and Clinical Reporting
Clinical results are provided in an intuitive, user-friendly report
Publications
Trophoblast Retrieval and Isolation from the Cervix (TRIC) for Noninvasive Prenatal Screening at 5 to 20 Weeks of Gestation
Trophoblast Retrieval and Isolation from the Cervix (TRIC) is Unaffected by Early Gestational Age or Maternal Obesity
Fetal Genome Profiling at 5 Weeks of Gestation After Noninvasive Isolation of Trophoblast Cells from the Endocervical Canal
Altered Biomarkers in Trophoblast Cells Obtained Noninvasively Prior to Clinical Manifestation of Perinatal Disease
Trophoblast Retrieval and Isolation from the Cervix: Origins of Cervical Trophoblasts and Their Potential Value for Risk Assessment of Ongoing Pregnancies